The consensus among analysts is that Myovant Sciences Ltd. (MYOV) is a Buy stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.68.
Myovant Sciences Ltd. (NYSE:MYOV) trade information
Despite being -5.25% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Jun 24 when the MYOV stock price touched $22.07- or saw a rise of 12.44%. Year-to-date, Myovant Sciences Ltd. shares have moved 24.48%, while the 5-day performance has seen it change 10.97%. Over the past 30 days, the shares of Myovant Sciences Ltd. (NYSE:MYOV) have changed 57.71%. Short interest in the company has seen 3.01 Million shares shorted with days to cover at 2.21.
Myovant Sciences Ltd. (MYOV) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest +17.7% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Myovant Sciences Ltd. (NYSE:MYOV)’s Major holders
Insiders own 59.91% of the company shares, while shares held by institutions stand at 37.6% with a share float percentage of 93.78%. Investors are also buoyed by the number of investors in a company, with Myovant Sciences Ltd. having a total of 93 institutions that hold shares in the company. The top two institutional holders are Bellevue Group AG with over 4.82 Million shares worth more than $36.35 Million. As of March 30, 2020, Bellevue Group AG held 5.36% of shares outstanding.
The other major institutional holder is Janus Henderson Group PLC, with the holding of over 4.71 Million shares as of March 30, 2020. The firm’s total holdings are worth over $35.59 Million and represent 5.24% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Janus Henderson Global Life Sciences Fund. As of December 30, 2019, the former fund manager holds about 2.86% shares in the company for having 2570583 shares of worth $39.9 Million while later fund manager owns 1.6 Million shares of worth $24.85 Million as of December 30, 2019, which makes it owner of about 1.78% of company’s outstanding stock.